Marco Gatti1, Marco Calandri2, Laura Bergamasco3, Fatemeh Darvizeh3, Luigi Grazioli4, Riccardo Inchingolo5, Davide Ippolito6,7, Stefano Rousset3, Andrea Veltri2, Paolo Fonio3, Riccardo Faletti3. 1. Department of Surgical Sciences, Radiology Unit, University of Turin, Via Genova 3, 10126, Turin, Italy. marcogatti17@gmail.com. 2. Department of Oncology, Radiology Unit, University of Torino, Turin, Italy. 3. Department of Surgical Sciences, Radiology Unit, University of Turin, Via Genova 3, 10126, Turin, Italy. 4. Department of Radiology, University of Brescia "Spedali Civili", P.le Spedali Civili 1, 25123, Brescia, Italy. 5. Division of Interventional Radiology, Department of Radiology, Madonna delle Grazie Hospital, 75100, Matera, Italy. 6. School of Medicine, University of Milano-Bicocca, Milan, Italy. 7. Department of Diagnostic Radiology, H. S. Gerardo Monza, Via Pergolesi 33, 20900, Monza, MB, Italy.
Abstract
PURPOSE: To evaluate the features of arterial enhancement pattern of focal nodular hyperplasia (FNH) and hepatocellular carcinoma (HCC) by triple-phase arterial magnetic resonance imaging (MRI). METHODS: Data were retrospectively collected from 52 consecutive patients who underwent triple-phase arterial MRI using hepatocyte-specific contrast agents (Gd-EOB-DTPA) from January 2017 to October 2017, with a MR imaging diagnosis of HCC or FNH. The images were independently assessed by two blinded readers. Contrast enhancement ratio (CER) and liver-to-lesion contrast ratio (LLCR) were calculated. The lesions were classified visually and also based on the peak of LLCR into the following groups: (1) early arterial, (2) middle arterial and (3) late arterial. Data were eventually analysed using nonparametric tests. RESULTS: The CER analysis showed no significant difference between HCC and FNH patients (p > 0.05). LLCRFNH were significantly higher than LLCRHCC in the early arterial (p = 0.01), but not in the middle and late arterial phases (p = 0.20 and p = 0.82, respectively). LLCRHCC presented a meaningful increase from early to middle arterial phase (p = 0.009), whereas LLCRFNH showed a decrease from middle to late arterial phase (p = 0.004). Based on the peak of LLCR, 17 (55%) FNHs were classified into early, 11 (35%) in middle and only 3 (10%) in late arterial phase groups. Similarly, 14 (34%) HCCs were categorized into early, 13 (32%) in middle and 14 (33%) in late arterial phase groups. There was a good agreement between qualitative analysis and LLCR in 85% of cases. CONCLUSION: The optimal visualization of FNH has been detected in early and middle arterial phases while HCC has been best observed during middle and late arterial phases.
PURPOSE: To evaluate the features of arterial enhancement pattern of focal nodular hyperplasia (FNH) and hepatocellular carcinoma (HCC) by triple-phase arterial magnetic resonance imaging (MRI). METHODS: Data were retrospectively collected from 52 consecutive patients who underwent triple-phase arterial MRI using hepatocyte-specific contrast agents (Gd-EOB-DTPA) from January 2017 to October 2017, with a MR imaging diagnosis of HCC or FNH. The images were independently assessed by two blinded readers. Contrast enhancement ratio (CER) and liver-to-lesion contrast ratio (LLCR) were calculated. The lesions were classified visually and also based on the peak of LLCR into the following groups: (1) early arterial, (2) middle arterial and (3) late arterial. Data were eventually analysed using nonparametric tests. RESULTS: The CER analysis showed no significant difference between HCC and FNHpatients (p > 0.05). LLCRFNH were significantly higher than LLCRHCC in the early arterial (p = 0.01), but not in the middle and late arterial phases (p = 0.20 and p = 0.82, respectively). LLCRHCC presented a meaningful increase from early to middle arterial phase (p = 0.009), whereas LLCRFNH showed a decrease from middle to late arterial phase (p = 0.004). Based on the peak of LLCR, 17 (55%) FNHs were classified into early, 11 (35%) in middle and only 3 (10%) in late arterial phase groups. Similarly, 14 (34%) HCCs were categorized into early, 13 (32%) in middle and 14 (33%) in late arterial phase groups. There was a good agreement between qualitative analysis and LLCR in 85% of cases. CONCLUSION: The optimal visualization of FNH has been detected in early and middle arterial phases while HCC has been best observed during middle and late arterial phases.
Authors: Nabia S Ikram; Judy Yee; Stefanie Weinstein; Benjamin M Yeh; Carlos U Corvera; Alexander Monto; Thomas A Hope Journal: Abdom Radiol (NY) Date: 2017-03
Authors: J Y Scoazec; J F Flejou; A D'Errico; A Couvelard; R Kozyraki; M Fiorentino; W F Grigioni; G Feldmann Journal: Hum Pathol Date: 1995-10 Impact factor: 3.466
Authors: E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi Journal: Eur Radiol Date: 2015-07-21 Impact factor: 5.315
Authors: Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo Journal: Infect Agent Cancer Date: 2021-07-19 Impact factor: 2.965
Authors: Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Mauro Piccirillo; Silvia Pradella; Marzia Giordano; Salvatore Cappabianca; Luca Brunese; Roberto Grassi; Antonella Petrillo; Francesco Izzo Journal: Int J Environ Res Public Health Date: 2021-03-30 Impact factor: 3.390
Authors: Marco Fronda; Andrea Doriguzzi Breatta; Marco Gatti; Marco Calandri; Claudio Maglia; Laura Bergamasco; Dorico Righi; Riccardo Faletti; Paolo Fonio Journal: Eur Radiol Date: 2021-03-18 Impact factor: 5.315